当前位置: X-MOL 学术World J. Surg. Onc. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical application of gelatin sponge microparticles combined with pirarubicin for hepatic transcatheter arterial chemoembolization in breast cancer liver metastasis treatment: results of a single-center long-term study
World Journal of Surgical Oncology ( IF 3.2 ) Pub Date : 2021-08-21 , DOI: 10.1186/s12957-021-02332-0
Guang Sheng Zhao 1 , Song Liu 2 , Ying Liu 3 , Jian Ma 1 , Ruo Yu Wang 4 , Jie Bian 5 , Jun Zhou 1 , Jian Lin Wu 6 , Yue Wei Zhang 3
Affiliation  

To retrospectively analyze the safety and long-term clinical efficacy of gelatin sponge microparticles combined with the chemotherapy drug pirarubicin for hepatic transcatheter arterial chemoembolization (GSMs-TACE) in order to treat breast cancer liver metastasis (BCLM). Twenty-seven BCLM patients who underwent GSMs-TACE from July 2010 to July 2016 were enrolled. Tumor target blood vessels were slowly and regionally embolized with absorbable gelatin sponge particles and pirarubicin injections. Plain computed tomography (CT) scans and biochemical indexes were re-examined at 4 days after treatment, and enhanced CT scans or magnetic resonance images and biochemical indexes, 1 month later. For patients with stable tumors, the follow-up period was 2 to 3 months, and the tumor response was evaluated using Modified Response Evaluation Criteria in Solid Tumors. Adverse reactions, survival time, and prognostic factors were assessed. By October 2019, 27 patients with BCLM had undergone GSMs-TACE, with an average of 2.44 ± 1.58 treatments. The 1-, 3-, and 5-year survival rates were 62.96%, 22.22%, and 14.81%, respectively, and the mOS was 22.0 months. No serious complications, such as acute liver failure and liver abscess, had occurred. There were two cases of acute cholecystitis that recovered after symptomatic treatment. Multivariate analysis of the prognosis showed that the primary tumor size, number of metastatic lymph nodes, estrogen receptor/progesterone receptor (ER/PR) status, and time to postoperative liver metastasis and combination therapy were statistically significant. The overall prognosis of BCLM was poor. GSMs-TACE was safe and effective for BCLM treatment and could prolong the median survival time of patients. Therefore, it is worthy of widespread clinical application.

中文翻译:

明胶海绵微粒联合吡柔比星经肝动脉化疗栓塞治疗乳腺癌肝转移的临床应用:单中心长期研究结果

回顾性分析明胶海绵微粒联合化疗药物吡柔比星用于肝动脉化疗栓塞术(GSMs-TACE)治疗乳腺癌肝转移(BCLM)的安全性和远期临床疗效。2010 年 7 月至 2016 年 7 月期间接受了 GSMs-TACE 的 27 名 BCLM 患者被纳入研究。用可吸收的明胶海绵颗粒和吡柔比星注射剂缓慢地局部栓塞肿瘤靶血管。治疗后4天复查CT平扫及生化指标,1个月后复查CT增强或磁共振影像及生化指标。对于肿瘤稳定的患者,随访时间为2~3个月,并且使用实体瘤中的改良反应评估标准评估肿瘤反应。评估不良反应、生存时间和预后因素。到 2019 年 10 月,27 名 BCLM 患者接受了 GSMs-TACE,平均 2.44 ± 1.58 次治疗。1年、3年和5年生存率分别为62.96%、22.22%和14.81%,mOS为22.0个月。未发生急性肝功能衰竭、肝脓肿等严重并发症。有2例急性胆囊炎经对症治疗后痊愈。预后的多变量分析显示原发肿瘤大小、转移淋巴结数量、雌激素受体/孕激素受体(ER/PR)状态、术后肝转移时间和联合治疗具有统计学意义。BCLM 的总体预后较差。GSMs-TACE 治疗 BCLM 安全有效,可延长患者的中位生存时间。因此,值得临床广泛应用。
更新日期:2021-08-23
down
wechat
bug